Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Xueshuai Ye"'
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-18 (2022)
Abstract Background Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the adoptive immunotherapy of which is worth studying. CD133, a kind of cancer stem cell (CSC) antigen, together with glypican-3 (GPC3) has been proved
Externí odkaz:
https://doaj.org/article/20f59a64f6684b89b206e3d1763b9bf8
Autor:
Haiqiang Zhang, Xueshuai Ye, Junye Wen, Ziqi Cai, Yang Li, Mengya Zhang, Li Shen, Jianhui Cai
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract HER-2 targeted therapies, such as monoclonal antibodies (mAbs) and CAR-T cell therapy have been applied in the treatment of various of cancers. However, the anti-HER2 CAR-T cell therapy are limited by its expensive production procedure and f
Externí odkaz:
https://doaj.org/article/8da721737eb7477e829a7ec04c0cccdc
Manufacturing CAR (chimeric antigen receptor)-T cell with viral vector is expensive and time-consuming. Besides, during viral transduction, the genes encoding CARs are randomly integrated into the genome, which could cause oncogenesis or produce deva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e952e09fadbecc9838620958b2f89b62
https://doi.org/10.1101/2022.11.25.517980
https://doi.org/10.1101/2022.11.25.517980
Autor:
Mengya Zhang, Hezhi Wang, Pingping Du, Yang Li, Jianhui Cai, Ziqi Cai, Yi Ju, Xueshuai Ye, Xiaoxiao Wang
Publikováno v:
OncoTargets and Therapy. 13:3703-3716
Purpose Based on the continuous exploration of solid tumor immunotherapy, we focused on hepatocellular carcinoma with a high level of morbidity and mortality. We confirm the stability of mcDNA-based CAR T cell generating platform, and investigate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::733fdfb9ab78543f19e5413dc80169df
https://doi.org/10.2147/ott.s247836
https://doi.org/10.2147/ott.s247836
Autor:
Xueshuai, Ye, Xinna, Deng, Junye, Wen, Yang, Li, Mengya, Zhang, Ziqi, Cai, Guan, Liu, Hezhi, Wang, Jianhui, Cai
Publikováno v:
Journal of oncology. 2022
Triple-negative breast cancer (TNBC) is the worst prognosis subtype of breast cancer due to lack of specific targets. Recent studies have shown that immunotherapy may solve that problem by targeting folate receptor-alpha (FRGene modified7 × 19 CAR-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::910d100a29605b30be783076a8c7b39b
https://pubmed.ncbi.nlm.nih.gov/35295709
https://pubmed.ncbi.nlm.nih.gov/35295709
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the adoptive immunotherapy of which is worth studying. CD133, a kind of cancer stem cell (CSC) antigen, together with glypican-3 (GPC3) have been proved to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec660868407edbeca63eee99197298bd
https://doi.org/10.21203/rs.3.rs-1039651/v1
https://doi.org/10.21203/rs.3.rs-1039651/v1
Autor:
Haiqiang Zhang, Xueshuai Ye, Junye Wen, Ziqi Cai, Yang Li, Mengya Zhang, Li Shen, Jianhui Cai
Publikováno v:
Scientific reports. 12(1)
HER-2 targeted therapies, such as monoclonal antibodies (mAbs) and CAR-T cell therapy have been applied in the treatment of various of cancers. However, the anti-HER2 CAR-T cell therapy are limited by its expensive production procedure and fatal side
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6b1f0dbd364594f68886b8e7f627b6b
https://pubmed.ncbi.nlm.nih.gov/35729189
https://pubmed.ncbi.nlm.nih.gov/35729189
Autor:
Jianhui Cai, Li Shen, Jiantao Dong, Yang Li, Xueqian Zhang, Ziqi Cai, Mengya Zhang, Ye Zhou, Xueshuai Ye, Wanxing Zhang
Publikováno v:
Biochemical and biophysical research communications. 584
Umbilical cord mesenchymal stem cells (UC-MSCs) transplantation has become a promising treatment for liver fibrosis. However, UC-MSCs have limited anti-fibrosis ability, and their homing ability of UC-MSCs to the injured liver seems to be poor. In ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba88db97f07b00d7809e6eb88c9678d2
https://pubmed.ncbi.nlm.nih.gov/34775285
https://pubmed.ncbi.nlm.nih.gov/34775285
Autor:
Yang Li, Xueshuai Ye, Xueqian Zhang, Ziqi Cai, Li Shen, Mengya Zhang, Wentao Zhang, Jianhui Cai
Background: Umbilical cord mesenchymal stem cells (UC-MSCs) transplantation have become a promising treatment for liver fibrosis. However, UC-MSCs have limited anti-fibrosis ability, and their homing ability of UC-MSCs to the injured liver sites appe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2794d3dcc0cd6e3ca82aba149abdf9ff
https://doi.org/10.21203/rs.3.rs-742448/v1
https://doi.org/10.21203/rs.3.rs-742448/v1
Autor:
Hezhi Wang, Xueshuai Ye, Yi Ju, Ziqi Cai, Xiaoxiao Wang, Pingping Du, Mengya Zhang, Yang Li, Jianhui Cai
Publikováno v:
OncoTargets and Therapy. 13:5707-5708
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37525a79d36fe0a11109683fee2ff777
https://doi.org/10.2147/ott.s267121
https://doi.org/10.2147/ott.s267121